Delivering fixed-dose combination therapies with hard capsules
The global pharmaceutical manufacturing market was valued at $405.52 billion in 2020 and is projected to increase at a compound annual growth rate of 11.34% between 2021 and 2028.1Get more news about Maca Hard Capsules,you can vist our website!
Substantial capital investments have also been seen in R&D and digital innovation.2 This emphasis on innovation has made it imperative for pharmaceutical companies to demonstrate competitive advantages in the market, particularly in light of cut-throat rivalry playing out with both branded and generic products.3
Owing to this competitive environment, there is a need for different strategies to deal with the ever-changing market ecosystem. A key focus when it comes to maintaining and building market share is new product development (NPD).4
As a result, companies are grappling to distinguish themselves in this field and demonstrate how successful they can be.
Product lifecycle management, technology amalgams and patient-centric approaches are the trends that have added to the importance of creating new avenues in product development.
Innovation in NPD can take different routes, such as incorporating novel drug forms (such as a salt or isomers), new therapeutic indications for older molecules or creating new dosage forms with enhanced efficacy.
Combination therapy is another key focus for product development. It consists of two or more drugs with complementary modes of action that can be used when there is a need for multiple drugs to treat a single disease.5
What is a fixed-dose combination?
A drug or fixed-dose combination (FDC) is a dosage form consisting of two or more active ingredients in a particular fixed dose (such as Atenolol + Nifedipine in a capsule).
FDCs are becoming more prevalent as they increasingly become part of product-cycle management strategies to expand the intellectual property rights exposure of older pharmaceutical products.6
In the healthcare industry, multiple drugs are prescribed to treat various diseases and medical conditions, including hypertension, tuberculosis, diabetes, respiratory diseases, cancer and HIV.
The rationales for this are many, as it is better to combine two or more drugs for better efficacy rather than increase the dose of a single drug. On several occasions synergistic drug combinations have shown benefits compared with single drug therapies, including increased efficacy, decreased dosage with equal efficacy and reduced side-effects.
Apart from being synergistic, if drugs with different mechanisms of action for the same therapeutic indication are given, then the overall patient outcome may also improve.
